iCAD, Inc. a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD.
As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnerships, operations and customer success.
Mark Koeniguer brings more than 30 years of experience leading and scaling MedTech, AI, and digital health companies to iCAD. Most recently, he served as CEO of ScreenPoint Medical, where he transformed the company from a science-led organization into a global commercial enterprise, increasing annual recurring revenue by 400% and launching two FDA-cleared products. He previously held executive leadership roles at Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis and GE Healthcare where he drove revenue growth and led successful product launches.
Also Read: Hillstrong Group Security Appoints William Noto as CRO to Accelerate SaaS-Powered Operational Risk Intelligence Platform
Dana Brown, President and CEO of iCAD commented, “Mark’s deep expertise in the radiological health market and AI-powered solutions makes him an ideal leader for this new role. As Chief Commercial Officer, he will be instrumental in positioning iCAD to better engage with global health providers seeking enterprise-wide solutions that elevate both clinical workflows and patient experiences. We are excited to welcome Mark to the team as we continue advancing our mission to transform breast cancer detection.”
“Mark brings extensive industry experience in breast health, diagnostics, and medical solutions from his previous leadership roles at ScreenPoint, Volpara, and GE Healthcare, and his technical understanding of imaging workflows and partner-oriented consultative approach make him well-suited to fuel iCAD’s continued growth,” said Michelle Strong, Chief Operations Officer of iCAD. “We are thrilled to welcome Mark to iCAD where he can be influential in bringing iCAD’s AI-powered suite of ProFound breast cancer detection and risk assessment solutions to more women, everywhere, helping create a world where cancer can’t hide.”
Source: GlobeNewswire
, to lead the next phase of global growth for iCAD.){kind=link}